406 related articles for article (PubMed ID: 24794900)
1. EPR: Evidence and fallacy.
Nichols JW; Bae YH
J Control Release; 2014 Sep; 190():451-64. PubMed ID: 24794900
[TBL] [Abstract][Full Text] [Related]
2. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS.
Fang J; Sawa T; Maeda H
Adv Exp Med Biol; 2003; 519():29-49. PubMed ID: 12675206
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS.
Maeda H; Sawa T; Konno T
J Control Release; 2001 Jul; 74(1-3):47-61. PubMed ID: 11489482
[TBL] [Abstract][Full Text] [Related]
4. Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors.
Nagamitsu A; Greish K; Maeda H
Jpn J Clin Oncol; 2009 Nov; 39(11):756-66. PubMed ID: 19596662
[TBL] [Abstract][Full Text] [Related]
5. [Arterial infusion chemotherapy with SMANCS].
Nekohashi T; Maruno J; Sanjou A; Toda G
Nihon Rinsho; 2001 Oct; 59 Suppl 6():629-33. PubMed ID: 11762025
[No Abstract] [Full Text] [Related]
6. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect.
Maeda H; Bharate GY; Daruwalla J
Eur J Pharm Biopharm; 2009 Mar; 71(3):409-19. PubMed ID: 19070661
[TBL] [Abstract][Full Text] [Related]
7. [Effect of arterial administration of a high molecular weight anti-tumor agent styrene maleic acid neocarzinostatin for multiple small liver cancer].
Ikeda K; Saitoh S; Kumada H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():19-23. PubMed ID: 9512682
[TBL] [Abstract][Full Text] [Related]
8. [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Maeda H; Konno T
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):773-82. PubMed ID: 2985005
[TBL] [Abstract][Full Text] [Related]
9. Role of integrated cancer nanomedicine in overcoming drug resistance.
Iyer AK; Singh A; Ganta S; Amiji MM
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
[TBL] [Abstract][Full Text] [Related]
10. Passive tumor targeting of soluble macromolecules and drug conjugates.
Seymour LW
Crit Rev Ther Drug Carrier Syst; 1992; 9(2):135-87. PubMed ID: 1386002
[TBL] [Abstract][Full Text] [Related]
11. [Pathologic study of hepatocellular carcinoma treated by TAI and TAE with SMANCS].
Takayasu K; Iwata R; Furukawa T; Nakanishi Y; Sakamoto M
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():70-2. PubMed ID: 9512691
[No Abstract] [Full Text] [Related]
12. [Significance of arterial infusion of SMANCS-dissolved Lipiodol in therapeutic strategies for hepatocellular carcinoma].
Jin-no K
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():90-8. PubMed ID: 9512695
[TBL] [Abstract][Full Text] [Related]
13. [SMANCS/lipiodol].
Maeda H
Gan To Kagaku Ryoho; 1994 May; 21(6):907-13. PubMed ID: 8185354
[TBL] [Abstract][Full Text] [Related]
14. Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting.
Greish K
Methods Mol Biol; 2010; 624():25-37. PubMed ID: 20217587
[TBL] [Abstract][Full Text] [Related]
15. Passive and active drug targeting: drug delivery to tumors as an example.
Torchilin VP
Handb Exp Pharmacol; 2010; (197):3-53. PubMed ID: 20217525
[TBL] [Abstract][Full Text] [Related]
16. [Clinical application and significance of drug delivery systems in cancer chemotherapy].
Tsukagoshi S
Nihon Rinsho; 1989 Jun; 47(6):1295-301. PubMed ID: 2528007
[No Abstract] [Full Text] [Related]
17. Anticancer nanomedicine and tumor vascular permeability; Where is the missing link?
Taurin S; Nehoff H; Greish K
J Control Release; 2012 Dec; 164(3):265-75. PubMed ID: 22800576
[TBL] [Abstract][Full Text] [Related]
18. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy--Problems, Solutions, and Prospects.
Maeda H; Tsukigawa K; Fang J
Microcirculation; 2016 Apr; 23(3):173-82. PubMed ID: 26237291
[TBL] [Abstract][Full Text] [Related]
19. Towards Optimal Design of Cancer Nanomedicines: Multi-stage Nanoparticles for the Treatment of Solid Tumors.
Stylianopoulos T; Economides EA; Baish JW; Fukumura D; Jain RK
Ann Biomed Eng; 2015 Sep; 43(9):2291-300. PubMed ID: 25670323
[TBL] [Abstract][Full Text] [Related]
20. [Recent advances in research on SMANCS].
Maeda H
Gan To Kagaku Ryoho; 1998 Feb; 25 Suppl 1():1-9. PubMed ID: 9512680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
